[Impulse control disorders in Parkinson's disease: A cohort of 35 patients].
Identifieur interne : 000E18 ( Ncbi/Merge ); précédent : 000E17; suivant : 000E19[Impulse control disorders in Parkinson's disease: A cohort of 35 patients].
Auteurs : N. Carrière [France] ; A. Kreisler ; K. Dujardin ; A. Destée ; L. DefebvreSource :
- Revue neurologique [ 0035-3787 ] ; 2012.
English descriptors
- KwdEn :
- Adult, Age of Onset, Aged, Antiparkinson Agents (administration & dosage), Case-Control Studies, Cohort Studies, Disruptive, Impulse Control, and Conduct Disorders (complications), Disruptive, Impulse Control, and Conduct Disorders (diagnosis), Disruptive, Impulse Control, and Conduct Disorders (drug therapy), Disruptive, Impulse Control, and Conduct Disorders (epidemiology), Dopamine Agonists (administration & dosage), Dopamine Agonists (adverse effects), Dose-Response Relationship, Drug, Female, Humans, Levodopa (administration & dosage), Male, Middle Aged, Parkinson Disease (complications), Parkinson Disease (diagnosis), Parkinson Disease (drug therapy), Parkinson Disease (epidemiology), Retrospective Studies, Socioeconomic Factors, Withholding Treatment (statistics & numerical data).
- MESH :
- chemical , administration & dosage : Antiparkinson Agents, Dopamine Agonists, Levodopa.
- chemical , adverse effects : Dopamine Agonists.
- complications : Disruptive, Impulse Control, and Conduct Disorders, Parkinson Disease.
- diagnosis : Disruptive, Impulse Control, and Conduct Disorders, Parkinson Disease.
- drug therapy : Disruptive, Impulse Control, and Conduct Disorders, Parkinson Disease.
- epidemiology : Disruptive, Impulse Control, and Conduct Disorders, Parkinson Disease.
- statistics & numerical data : Withholding Treatment.
- Adult, Age of Onset, Aged, Case-Control Studies, Cohort Studies, Dose-Response Relationship, Drug, Female, Humans, Male, Middle Aged, Retrospective Studies, Socioeconomic Factors.
Abstract
Impulse control disorders (ICDs) in Parkinson's disease (PD) are associated with dopamine agonist treatment. Although discontinuation of dopamine agonist is recommended, ICD management has not been precisely stated. The aims of the study were to describe demographic and clinical characteristics in a group of PD patients with ICDs and to evaluate the management of dopamine agonist treatment proposed to the same patients in order to treat the ICDs.
DOI: 10.1016/j.neurol.2011.07.010
PubMed: 22129474
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000893
- to stream PubMed, to step Curation: 000857
- to stream PubMed, to step Checkpoint: 000857
Links to Exploration step
pubmed:22129474Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Impulse control disorders in Parkinson's disease: A cohort of 35 patients].</title><author><name sortKey="Carriere, N" sort="Carriere, N" uniqKey="Carriere N" first="N" last="Carrière">N. Carrière</name><affiliation wicri:level="3"><nlm:affiliation>Université Lille-Nord-de-France, 1 bis, rue Georges-Lefèvre, 59000 Lille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Université Lille-Nord-de-France, 1 bis, rue Georges-Lefèvre, 59000 Lille</wicri:regionArea><placeName><region type="region" nuts="2">Hauts-de-France</region><region type="old region" nuts="2">Nord-Pas-de-Calais</region><settlement type="city">Lille</settlement></placeName></affiliation></author><author><name sortKey="Kreisler, A" sort="Kreisler, A" uniqKey="Kreisler A" first="A" last="Kreisler">A. Kreisler</name></author><author><name sortKey="Dujardin, K" sort="Dujardin, K" uniqKey="Dujardin K" first="K" last="Dujardin">K. Dujardin</name></author><author><name sortKey="Destee, A" sort="Destee, A" uniqKey="Destee A" first="A" last="Destée">A. Destée</name></author><author><name sortKey="Defebvre, L" sort="Defebvre, L" uniqKey="Defebvre L" first="L" last="Defebvre">L. Defebvre</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2012">2012</date><idno type="RBID">pubmed:22129474</idno><idno type="pmid">22129474</idno><idno type="doi">10.1016/j.neurol.2011.07.010</idno><idno type="wicri:Area/PubMed/Corpus">000893</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000893</idno><idno type="wicri:Area/PubMed/Curation">000857</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000857</idno><idno type="wicri:Area/PubMed/Checkpoint">000857</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000857</idno><idno type="wicri:Area/Ncbi/Merge">000E18</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[Impulse control disorders in Parkinson's disease: A cohort of 35 patients].</title><author><name sortKey="Carriere, N" sort="Carriere, N" uniqKey="Carriere N" first="N" last="Carrière">N. Carrière</name><affiliation wicri:level="3"><nlm:affiliation>Université Lille-Nord-de-France, 1 bis, rue Georges-Lefèvre, 59000 Lille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Université Lille-Nord-de-France, 1 bis, rue Georges-Lefèvre, 59000 Lille</wicri:regionArea><placeName><region type="region" nuts="2">Hauts-de-France</region><region type="old region" nuts="2">Nord-Pas-de-Calais</region><settlement type="city">Lille</settlement></placeName></affiliation></author><author><name sortKey="Kreisler, A" sort="Kreisler, A" uniqKey="Kreisler A" first="A" last="Kreisler">A. Kreisler</name></author><author><name sortKey="Dujardin, K" sort="Dujardin, K" uniqKey="Dujardin K" first="K" last="Dujardin">K. Dujardin</name></author><author><name sortKey="Destee, A" sort="Destee, A" uniqKey="Destee A" first="A" last="Destée">A. Destée</name></author><author><name sortKey="Defebvre, L" sort="Defebvre, L" uniqKey="Defebvre L" first="L" last="Defebvre">L. Defebvre</name></author></analytic><series><title level="j">Revue neurologique</title><idno type="ISSN">0035-3787</idno><imprint><date when="2012" type="published">2012</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Age of Onset</term><term>Aged</term><term>Antiparkinson Agents (administration & dosage)</term><term>Case-Control Studies</term><term>Cohort Studies</term><term>Disruptive, Impulse Control, and Conduct Disorders (complications)</term><term>Disruptive, Impulse Control, and Conduct Disorders (diagnosis)</term><term>Disruptive, Impulse Control, and Conduct Disorders (drug therapy)</term><term>Disruptive, Impulse Control, and Conduct Disorders (epidemiology)</term><term>Dopamine Agonists (administration & dosage)</term><term>Dopamine Agonists (adverse effects)</term><term>Dose-Response Relationship, Drug</term><term>Female</term><term>Humans</term><term>Levodopa (administration & dosage)</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (diagnosis)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (epidemiology)</term><term>Retrospective Studies</term><term>Socioeconomic Factors</term><term>Withholding Treatment (statistics & numerical data)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparkinson Agents</term><term>Dopamine Agonists</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Dopamine Agonists</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Disruptive, Impulse Control, and Conduct Disorders</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Disruptive, Impulse Control, and Conduct Disorders</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Disruptive, Impulse Control, and Conduct Disorders</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Disruptive, Impulse Control, and Conduct Disorders</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Withholding Treatment</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Age of Onset</term><term>Aged</term><term>Case-Control Studies</term><term>Cohort Studies</term><term>Dose-Response Relationship, Drug</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Retrospective Studies</term><term>Socioeconomic Factors</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Impulse control disorders (ICDs) in Parkinson's disease (PD) are associated with dopamine agonist treatment. Although discontinuation of dopamine agonist is recommended, ICD management has not been precisely stated. The aims of the study were to describe demographic and clinical characteristics in a group of PD patients with ICDs and to evaluate the management of dopamine agonist treatment proposed to the same patients in order to treat the ICDs.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22129474</PMID><DateCreated><Year>2012</Year><Month>03</Month><Day>05</Day></DateCreated><DateCompleted><Year>2012</Year><Month>07</Month><Day>10</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0035-3787</ISSN><JournalIssue CitedMedium="Internet"><Volume>168</Volume><Issue>2</Issue><PubDate><Year>2012</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Revue neurologique</Title><ISOAbbreviation>Rev. Neurol. (Paris)</ISOAbbreviation></Journal><ArticleTitle>[Impulse control disorders in Parkinson's disease: A cohort of 35 patients].</ArticleTitle><Pagination><MedlinePgn>143-51</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neurol.2011.07.010</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Impulse control disorders (ICDs) in Parkinson's disease (PD) are associated with dopamine agonist treatment. Although discontinuation of dopamine agonist is recommended, ICD management has not been precisely stated. The aims of the study were to describe demographic and clinical characteristics in a group of PD patients with ICDs and to evaluate the management of dopamine agonist treatment proposed to the same patients in order to treat the ICDs.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Thirty-five PD patients with ICD and 607 PD patients without ICD were studied. In the ICD group, demographic and clinical data were collected prospectively (ICD characteristics, motor and cognitive evaluation); demographic and clinical data were obtained retrospectively in the group without ICD.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In the ICD group, the sex ratio was 2.9 (versus 1.2 in the absence of ICD; p<0.05), the mean age was 57.5 years (versus 66.9 years; p<0.01) and the mean age at PD onset was 48.3 years (versus 55.5 years; p<0.01). All ICD patients were receiving a dopamine agonist when the ICD started (versus 50.9 % of patients receiving a dopamine agonist in the absence of ICD; p<10(-6)). In mean, ICDs started 2.8 years before they were diagnosed. No particular dopamine agonist was associated with ICDs more frequently than the others. Discontinuation of the dopamine agonist was the treatment the more frequently associated with the recovery of ICDs (93.3 %). Dose lowering and the change of dopamine agonist resulted in complete regression of ICDs respectively in 9.1% and 33.3% of patients.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Young age, male gender and young age at PD onset are frequent in PD patients developing ICDs, as already described in American or Asian cohorts. We highlighted a long diagnosis delay and confirmed the strong efficacy of dopamine agonist withdrawal.</AbstractText><CopyrightInformation>Copyright © 2011 Elsevier Masson SAS. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Carrière</LastName><ForeName>N</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Université Lille-Nord-de-France, 1 bis, rue Georges-Lefèvre, 59000 Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kreisler</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Dujardin</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Destée</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Defebvre</LastName><ForeName>L</ForeName><Initials>L</Initials></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Troubles du contrôle des impulsions associés à la maladie de Parkinson : étude d'une cohorte de 35 patients.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2011</Year><Month>11</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Rev Neurol (Paris)</MedlineTA><NlmUniqueID>2984779R</NlmUniqueID><ISSNLinking>0035-3787</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018491">Dopamine Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007174" MajorTopicYN="N">Disruptive, Impulse Control, and Conduct Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018491" MajorTopicYN="N">Dopamine Agonists</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012959" MajorTopicYN="N">Socioeconomic Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D028761" MajorTopicYN="N">Withholding Treatment</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>04</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2011</Year><Month>06</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>07</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>12</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>12</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>7</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22129474</ArticleId><ArticleId IdType="pii">S0035-3787(11)00375-4</ArticleId><ArticleId IdType="doi">10.1016/j.neurol.2011.07.010</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li></country><region><li>Hauts-de-France</li><li>Nord-Pas-de-Calais</li></region><settlement><li>Lille</li></settlement></list><tree><noCountry><name sortKey="Defebvre, L" sort="Defebvre, L" uniqKey="Defebvre L" first="L" last="Defebvre">L. Defebvre</name><name sortKey="Destee, A" sort="Destee, A" uniqKey="Destee A" first="A" last="Destée">A. Destée</name><name sortKey="Dujardin, K" sort="Dujardin, K" uniqKey="Dujardin K" first="K" last="Dujardin">K. Dujardin</name><name sortKey="Kreisler, A" sort="Kreisler, A" uniqKey="Kreisler A" first="A" last="Kreisler">A. Kreisler</name></noCountry><country name="France"><region name="Hauts-de-France"><name sortKey="Carriere, N" sort="Carriere, N" uniqKey="Carriere N" first="N" last="Carrière">N. Carrière</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E18 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000E18 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:22129474
|texte= [Impulse control disorders in Parkinson's disease: A cohort of 35 patients].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:22129474" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |